Subcutaneous semaglutide is the GLP-1 receptor agonist with the strongest randomized controlled trial evidence showing a significant reduction in liver fat content and resolution of NASH [55]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.